Falcon Point Capital LLC Cuts Holdings in Aclaris Therapeutics Inc (ACRS)

Falcon Point Capital LLC lowered its position in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 44.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,908 shares of the biotechnology company’s stock after selling 7,883 shares during the quarter. Falcon Point Capital LLC’s holdings in Aclaris Therapeutics were worth $244,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ACRS. FMR LLC raised its stake in Aclaris Therapeutics by 14.6% during the second quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock valued at $51,425,000 after buying an additional 242,269 shares in the last quarter. Alyeska Investment Group L.P. raised its stake in Aclaris Therapeutics by 85.2% during the third quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock valued at $12,076,000 after buying an additional 215,201 shares in the last quarter. Citadel Advisors LLC raised its stake in Aclaris Therapeutics by 620.6% during the third quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock valued at $6,247,000 after buying an additional 208,429 shares in the last quarter. State Street Corp raised its stake in Aclaris Therapeutics by 67.1% during the second quarter. State Street Corp now owns 330,755 shares of the biotechnology company’s stock valued at $8,971,000 after buying an additional 132,866 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Aclaris Therapeutics by 14.2% during the second quarter. Vanguard Group Inc. now owns 812,318 shares of the biotechnology company’s stock valued at $22,029,000 after buying an additional 100,799 shares in the last quarter. Hedge funds and other institutional investors own 92.47% of the company’s stock.

Shares of Aclaris Therapeutics Inc (ACRS) opened at $19.48 on Wednesday. Aclaris Therapeutics Inc has a 1 year low of $18.46 and a 1 year high of $33.25.

ACRS has been the topic of several research reports. Cantor Fitzgerald restated a “buy” rating and set a $50.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, November 7th. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, Guggenheim began coverage on Aclaris Therapeutics in a research note on Thursday, February 8th. They set a “buy” rating and a $53.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $41.80.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/falcon-point-capital-llc-cuts-holdings-in-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply